Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice

doi:10.1016/j.ijantimicag.2023.106953

Article

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice

16 Aug 2023

Abstract excerpt

Pretomanid (PA-824), a novel anti-tuberculosis (TB) nitroimidazoxazine, has been approved for multi-drug-resistant TB treatment for a few years. Pretomanid has been demonstrated to be highly active against Mycobacterium tuberculosis when combined with other anti-TB drugs. This review provides an update of the current knowledge on the modes of action, resistance mechanisms, emergence of drug resistance, and status...

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.